PHC Signs Overseas COVID-19 Diagnostic Business Agreement with Hanmi Pharm

[Asia Economy Reporter Hyungsoo Park] PHC and Hanmi Pharmaceutical announced on the 4th that they have signed a Memorandum of Understanding (MOU) to collaborate on the COVID-19 diagnostic business.

The MOU signing was attended by Choi Inhwan, CEO of PHC, and Kwon Sechang, President of Hanmi Pharmaceutical. They agreed to actively cooperate in developing saliva rapid antigen test kits and neutralizing antibody test kits under the Hanmi Pharmaceutical brand and exporting them overseas.

A PHC official stated, "Various diagnostic products, including the saliva rapid antigen test kit, will be combined with Hanmi Pharmaceutical's overseas distribution network," adding, "This will serve as an opportunity to widely promote the excellence of Korean diagnostic kits worldwide, including in the United States, Europe, Australia, and Southeast Asia."

Currently, rapid antigen tests using saliva have begun to be distributed overseas. As of last month, among the 29 self-test kits registered with the Australian TGA, 8 kits utilize saliva. In Germany, 8 kits also use saliva-based methods.

PHC received approval for its saliva rapid antigen test kit from the Australian Therapeutic Goods Administration (TGA). The sensitivity is 95.8%, ranking it among the top rapid antigen test kits registered in Australia.

This content was produced with the assistance of AI translation services.